Related by context. All words. (Click for frequent words.) 77 metastatic renal cell carcinoma 75 sorafenib Nexavar ® 74 alvespimycin 74 erlotinib Tarceva ® 74 recurrent NSCLC 74 ELACYT 74 metastatic hormone refractory 74 pertuzumab 73 mRCC 73 axitinib 73 standard chemotherapy regimen 73 Amrubicin 73 metastatic CRPC 73 metastatic castration resistant 72 HGS ETR1 72 gemcitabine chemotherapy 72 YONDELIS 72 sorafenib Nexavar 72 elotuzumab 72 relapsed refractory multiple myeloma 72 castration resistant prostate cancer 72 docetaxel Taxotere R 72 docetaxel chemotherapy 72 galiximab 72 sunitinib malate 72 relapsed MM 72 ErbB2 positive 72 pomalidomide 72 metastatic castrate resistant 72 glufosfamide 72 dasatinib Sprycel ® 72 neratinib 72 refractory metastatic 72 recurrent glioblastoma multiforme 72 hormone refractory prostate cancer 72 Aflibercept 72 leukemia AML 71 temsirolimus 71 HRPC 71 heavily pretreated 71 cetuximab Erbitux R 71 platinum refractory 71 pegylated liposomal doxorubicin 71 ZACTIMA 71 gefitinib Iressa 71 sorafenib tablets 71 enzastaurin 71 prostate cancer HRPC 71 trastuzumab Herceptin R 71 follicular NHL 71 bevacizumab Avastin ® 71 Bortezomib 71 MGd 71 metastatic renal cell 71 trastuzumab 71 mapatumumab 71 Aplidin 71 receptor tyrosine kinase inhibitor 70 HER2 + 70 adecatumumab 70 metastatic colorectal 70 panobinostat 70 metastatic HRPC 70 paclitaxel Taxol R 70 heavily pretreated patients 70 refractory multiple myeloma 70 neoadjuvant chemotherapy 70 Trastuzumab 70 HGS ETR2 70 metastatic colorectal cancer 70 carboplatin paclitaxel 70 Taxotere ® 70 entinostat 70 mCRC patients 70 imatinib Gleevec ® 70 CR# vcMMAE 70 Folfox 70 metastatic CRC 70 relapsed multiple myeloma 70 Tanespimycin 70 HER2 positive 70 pancreatic adenocarcinoma 70 evaluating tivozanib 70 dacarbazine 70 depsipeptide 70 HER2 negative 70 Imprime PGG 70 castrate resistant prostate cancer 70 FOLFIRI 70 cancer mCRC 70 PXD# 70 chlorambucil 69 relapsed ovarian cancer 69 metastatic RCC 69 dacarbazine DTIC 69 gemcitabine carboplatin 69 PSMA ADC 69 resistant ovarian cancer 69 Doxil ® 69 metastatic pancreatic 69 refractory AML 69 ixabepilone 69 Azedra 69 CYT# potent vascular disrupting 69 refractory cutaneous T 69 FOLFOX4 69 sorafenib Nexavar R 69 refractory chronic lymphocytic 69 leukemia CLL 69 docetaxel 69 advanced unresectable 69 standard chemotherapy regimens 69 Panzem R NCD 69 stage IIIB 69 gemcitabine Gemzar 69 T DM1 69 chronic lymphocytic leukemia CLL 69 Carfilzomib 69 glioblastoma multiforme GBM 69 elacytarabine 69 cediranib 69 metastatic androgen independent 69 Fludara 69 tanespimycin 69 diagnosed multiple myeloma 69 trastuzumab Herceptin ® 69 forodesine 69 metastatic malignant 69 dasatinib 69 HuMax EGFr 69 vandetanib 69 stage IIIb IV 69 TTF Therapy 69 Fludarabine 69 hormone refractory metastatic prostate 69 Irinotecan 69 assessing T DM1 69 metastatic gastric 69 differentiated thyroid 69 Velcade bortezomib 69 relapsed SCLC 69 IMA# 69 mCRC 69 dasatinib Sprycel 69 Zolinza 69 radiation sensitizer 69 Bezielle 69 EOquin TM 69 Fludara ® 69 oral ridaforolimus 69 neoadjuvant treatment 69 gemcitabine 69 refractory indolent non 68 lymphoid malignancies 68 anthracycline taxane 68 non squamous NSCLC 68 EndoTAGTM 1 68 BRIM2 68 Cloretazine ® 68 EGFR TKI 68 nab paclitaxel 68 metastatic breast cancer 68 afatinib 68 prostate cancer CRPC 68 ganetespib 68 evaluating Xcytrin 68 AVASTIN 68 Cloretazine 68 Cloretazine R VNP#M 68 iniparib 68 HGS# 68 IMGN# 68 estramustine 68 pemetrexed 68 gefitinib 68 KRAS mutations occur 68 registrational trial 68 Taxotere R 68 metastatic colorectal carcinoma 68 regorafenib 68 Herceptin trastuzumab 68 KRAS wild 68 Voreloxin 68 TYKERB 68 ZOLINZA 68 stage IIIB IV 68 systemic ALCL 68 BAY #-# 68 metastatic bladder 68 Bevacizumab 68 bevacizumab Avastin 68 cell lymphoma CTCL 68 Pertuzumab 68 xenograft models 68 Annamycin 68 advanced NSCLC 68 gemcitabine Gemzar ® 68 Hsp# Inhibitor 68 nilotinib Tasigna ® 68 previously untreated follicular 68 CIMZIA ™ 68 CANCIDAS 68 Gemzar ® 68 sunitinib 68 NSCLC 68 gastrointestinal stromal tumors GIST 68 cutaneous T cell 68 alkylating agent 68 AEG# 68 docetaxel Taxotere ® 68 fluoropyrimidine 68 taxane therapy 68 IMC A# 68 docetaxel Taxotere 68 Genasense ® 68 CHOP chemotherapy 68 evaluating T DM1 68 MAGE A3 ASCI 68 unresectable 68 Ceflatonin 68 demonstrated antitumor activity 68 Tarceva TM 68 Chronic Lymphocytic Leukemia CLL 68 PEG SN# 68 lymphoma CTCL 68 trastuzumab DM1 T DM1 68 low dose cytarabine 68 farletuzumab 68 plus dexamethasone 68 thalidomide Thalomid 67 INCB# [001] 67 chemotherapy regimens 67 superficial bladder cancer 67 ACTEMRA TM 67 LUX Lung 67 EGFR expressing mCRC 67 decitabine 67 goserelin 67 Temsirolimus 67 histologically confirmed 67 huN# DM1 67 DOXIL 67 KRAS status 67 hepatocellular cancer 67 phase IIb clinical 67 multiple myeloma MM 67 huC# DM4 67 FOLFOX6 67 bortezomib Velcade R 67 antibody MAb 67 azacytidine 67 vinca alkaloid 67 Phase #/#a trial 67 Perifosine 67 recurrent ovarian cancer 67 vorinostat 67 Pemetrexed 67 gastrointestinal stromal tumor GIST 67 pegylated interferon alfa 2a 67 Alocrest 67 irinotecan chemotherapy 67 romidepsin 67 bendamustine 67 trabectedin 67 advanced metastatic prostate 67 Ceplene/IL-2 67 trastuzumab DM1 67 unique alkylating agent 67 oral clodronate 67 indolent NHL 67 pazopanib 67 abiraterone acetate 67 IgG1 monoclonal antibody 67 advanced metastatic renal 67 recurrent metastatic 67 PI3K/Akt pathway inhibitor 67 IL# PE#QQR 67 EOquin TM phase 67 papillary renal cell carcinoma 67 SCCHN 67 Chemophase 67 chemoradiation therapy 67 nonmetastatic 67 custirsen 67 myelodysplastic myeloproliferative diseases 67 taxane refractory 67 Targretin 67 cetuximab Erbitux 67 metaglidasen 67 non metastatic osteosarcoma 67 GW# [003] 67 Brentuximab Vedotin SGN 67 ovarian carcinoma 67 plus prednisone 67 Proxinium TM 67 clinically localized prostate 67 infusional 5-FU/LV 67 phase IIb study 67 lintuzumab 67 fallopian tube carcinoma 67 gastrointestinal stromal tumors 67 neoadjuvant therapy 67 Nexavar ® 67 unresectable stage 67 Phase Ib II 67 MabCampath 67 5 fluorouracil leucovorin 67 VEGFR2 inhibitor 67 Vandetanib 67 recurrent glioblastoma 67 idarubicin 67 acute leukemias 67 Peginterferon alfa 2b 67 carboplatin 67 metastatic GIST 67 Neoadjuvant 67 CIMZIA TM 67 refractory NSCLC 67 Vicinium TM 67 lenalidomide Revlimid R 67 untreated multiple myeloma 67 bortezomib 67 NMIBC 67 LY# [003] 67 TORISEL 67 remission induction 66 malignant pleural mesothelioma 66 Allovectin 7 ® 66 imatinib Gleevec 66 oblimersen 66 sunitinib Sutent 66 doxorubicin HCl liposome injection 66 biologic therapy 66 EGFR inhibitors 66 deforolimus 66 TACE 66 liposomal doxorubicin 66 EGFR mutations 66 sunitinib Sutent ® 66 taxane 66 refractory colorectal cancer 66 Ozarelix 66 Hepatocellular Carcinoma HCC 66 CTAP# Capsules 66 aflibercept 66 chemoradiation 66 PKC# 66 Hormone Refractory Prostate Cancer 66 untreated metastatic colorectal 66 metastatic pancreatic cancer 66 evaluating picoplatin 66 neoadjuvant 66 capecitabine Xeloda 66 ofatumumab 66 Ophena TM 66 irinotecan doxorubicin oxaliplatin paclitaxel 66 tumors GIST 66 seliciclib 66 LHRH receptor positive 66 EGFr expressing metastatic colorectal 66 azacitidine 66 Cutaneous T 66 melphalan prednisone 66 Nexavar sorafenib 66 cisplatin chemotherapy 66 Triapine 66 Tesmilifene 66 ongoing Phase 1b 66 hematologic malignancies 66 cisplatin gemcitabine 66 VELCADE melphalan 66 cilengitide 66 unresectable Stage III 66 cutaneous T 66 erlotinib 66 Xanafide 66 Romidepsin 66 Dasatinib 66 unresectable locally advanced 66 mTOR inhibitor 66 Ocrelizumab 66 Metastatic Colorectal Cancer 66 HuLuc# 66 immunotherapeutic agent 66 IV NSCLC 66 paclitaxel cisplatin 66 cetuximab Erbitux ® 66 5 FU leucovorin 66 novel VDA molecule 66 talabostat 66 hA# 66 luteinizing hormone releasing 66 HER2 positive breast cancer 66 refractory CTCL 66 cytotoxic chemotherapy 66 metastatic renal 66 EGFR expressing 66 FOLFOX6 chemotherapy regimen 66 BCIRG 66 EOquin 66 Lenocta 66 thymalfasin 66 anticancer compound 66 radiation chemoradiation 66 relapsed refractory 66 INSPIRE Trial Phase III 66 histologies 66 chemotherapy cisplatin 66 unresectable tumors 66 FOLOTYN ® 66 MGCD# [001] 66 hematological cancers 66 metastatic HER2 negative 66 Archexin 66 trastuzumab emtansine T DM1 66 fludarabine 66 histone deacetylase HDAC inhibitor 66 paclitaxel Taxol ® 66 plus dacarbazine 66 paclitaxel carboplatin 66 orally administered inhibitor 66 EFAPROXYN 66 anthracyclines taxanes 66 advanced hepatocellular carcinoma 66 BRIM3 66 pan HDAC inhibitor 66 Troxatyl 66 basal cell carcinoma BCC 66 sorafenib 66 relapsed leukemia 66 lumiliximab 66 ThermoDox R 66 Traficet EN 66 Phase Ib study 66 Blinatumomab 66 cetuximab 66 Advanced Renal Cell 66 BRAF inhibitor 66 hormone receptor positive 66 Natalizumab 66 TEMODAL 66 systemic anaplastic large 66 aflibercept VEGF Trap 66 APTIVUS r 66 IRX 2 66 Aplidin R 66 biliary tract cancer 66 imetelstat 66 Phase 1b 66 K ras mutations 66 PROSTVAC VF 65 talactoferrin 65 Ixempra 65 brain metastases originating 65 Castration Resistant Prostate Cancer 65 TACI Ig 65 Platinol ® cisplatin 65 chemoradiotherapy 65 pegylated interferon alpha 65 nilotinib 65 Tyrima 65 bevacizumab Avastin R 65 3 registrational trial 65 PREZISTA r 65 CML CP 65 B CLL 65 belinostat 65 plus gemcitabine 65 familial amyloidotic polyneuropathy FAP 65 refractory CLL 65 colorectal liver metastases 65 SPRYCEL ® 65 squamous histology 65 FOLFOX 65 adjuvant chemotherapy 65 temozolomide 65 medically inoperable 65 pediatric acute lymphoblastic 65 zanolimumab 65 investigational humanized monoclonal antibody 65 Gemcitabine 65 antiangiogenic therapy 65 Bayer HealthCare Onyx Pharmaceuticals 65 Acute Myeloid Leukemia AML 65 registrational 65 taxane chemotherapy 65 monotherapy 65 panitumumab Vectibix 65 phase Ib 65 dexamethasone Decadron 65 dosing cohort 65 vinorelbine 65 advanced epithelial ovarian 65 adjuvant therapy 65 non squamous 65 REVIVE Diabetes 65 Glufosfamide 65 Gastrointestinal Stromal Tumors 65 AKT inhibitor 65 daunorubicin 65 FOLFOX regimen 65 ritonavir boosted 65 FUSILEV enhances 65 p# biomarker 65 antitumor activity 65 Enzastaurin 65 PEGylated interferon beta 1a 65 IMiDs ® 65 Marqibo TM 65 oral prodrug 65 IV metastatic melanoma 65 bone metastasis 65 lapatinib Tykerb 65 TRISENOX 65 intravesical infusion therapy 65 relapsed ALL 65 acute promyelocytic leukemia APL 65 interferon gamma 1b 65 Xeloda ® 65 virus HCV protease inhibitor 65 ER CHOP 65 Teriflunomide 65 FOLFOX chemotherapy 65 perifosine 65 Relapsed Refractory 65 chemotherapy FOLFOX 65 adalimumab Humira 65 oral deforolimus 65 acute myelogenous leukemia AML 65 anticancer therapy 65 OMP #R# 65 mycophenolate mofetil 65 Panzem NCD 65 Proellex TM 65 KRAS mutations 65 lintuzumab SGN 65 AP# [003] 65 mitoxantrone 65 refractory chronic myeloid 65 anti leukemic 65 imatinib resistant 65 Peginterferon 65 SUTENT 65 visilizumab 65 lapatinib 65 crizotinib PF # 65 breast carcinoma 65 HBeAg negative 65 ofatumumab HuMax CD# 65 bortezomib Velcade 65 ZK EPO 65 Talabostat 65 recurrent GBM 65 #I TM# 65 Diffuse Large B 65 cinacalcet 65 Hodgkin lymphoma HL 65 advanced carcinoid 65 acyclovir Lauriad R 65 invasive lobular carcinoma 65 leukemia ALL 65 PANVAC VF 65 radiolabeled TM# 65 preoperative chemotherapy 65 Lubiprostone 65 docetaxel prednisone 65 bosutinib 65 MDV# 65 Gliadel Wafer 65 nonsmall cell lung cancer 65 anti EGFR antibody 65 Revlimid lenalidomide 65 Clofarabine 65 myelofibrosis polycythemia vera 65 Pharmacokinetics PK 65 teriflunomide 65 Elotuzumab 65 PD LID 65 TREANDA 65 Hycamtin 65 situ CIS 65 IRESSA 65 IMiDs ® compound 65 trastuzumab Herceptin 65 relapsing multiple sclerosis 65 Anthracycline 65 APTIVUS 65 INCB# [003] 65 PDX pralatrexate 65 novel histone deacetylase 65 RGB # 65 epithelial tumors 65 dose cytarabine 65 follicular lymphoma FL 64 Panzem R 64 tyrosine kinase inhibitors 64 bevacizumab 64 solid tumors 64 RCW Breast Cancer 64 hormone receptor negative 64 OncoVEX GM CSF 64 BRCA deficient 64 Rebif ® 64 Gleevec Glivec 64 Quinamed 64 CTA# Injection 64 distant metastasis 64 5 Fluorouracil 64 Navelbine ® 64 ANYARA 64 Degarelix 64 Hedgehog Pathway Inhibitor 64 Epratuzumab 64 OMP #M# 64 tubulin inhibitor 64 amrubicin 64 Pegasys ® 64 gemcitabine cisplatin 64 epirubicin cyclophosphamide 64 untreated CLL 64 HCD# [002] 64 Camptosar ® 64 LEUKINE 64 cytoreductive nephrectomy 64 alfa 2a 64 bortezomib refractory 64 ara C 64 BCG refractory 64 pain palliation 64 CoFactor 64 oxaliplatin Eloxatin 64 chemotherapy docetaxel 64 thetreatment 64 XELOX 64 haematologic malignancies 64 KRN# 64 BEXXAR 64 MyVax R 64 EGFR HER2 64 evaluating ispinesib 64 concurrent chemoradiation 64 adjuvant radiation 64 lexidronam injection 64 hormone refractory 64 HuMax CD4 64 Vitaxin 64 interferon alfa 2a 64 CLL SLL 64 phase IIa clinical 64 Metastatic Renal Cell Carcinoma 64 medullary thyroid cancer 64 comparator arm 64 Telintra 64 plus DOXIL 64 EGFR expressing metastatic colorectal 64 allogeneic stem cell 64 tocilizumab 64 Capecitabine 64 LymphoStat B belimumab 64 lenalidomide dexamethasone 64 HCV SPRINT 64 BEXXAR Therapeutic Regimen 64 postoperative chemotherapy 64 Gleevec imatinib mesylate 64 eribulin mesylate 64 Seliciclib 64 relapsed refractory AML 64 liposomal formulation 64 BR.# 64 Philadelphia Chromosome Positive 64 MYLOTARG 64 primary hypercholesterolemia 64 alpha folate receptor 64 Clolar ® 64 cisplatin resistant 64 Akt inhibitor 64 AGILECT R 64 Torisel 64 Paraplatin ® carboplatin 64 mitoxantrone plus 64 stage IIIb 64 vidofludimus 64 diagnosed Ph + 64 ® lenalidomide 64 KNS # 64 refractory ovarian cancer 64 OPAXIO 64 xanthine oxidase inhibitor 64 Ixabepilone 64 rituximab refractory 64 Navelbine 64 adriamycin 64 IMiDs R 64 AQ4N 64 TRO# 64 Dapagliflozin 64 olaparib 64 panitumumab 64 antimetabolite 64 CINTREDEKIN BESUDOTOX 64 generation Hsp# inhibitor 64 imatinib therapy 64 APPRAISE 64 follicular non 64 chemotherapeutic regimen 64 CIMZIA TM certolizumab pegol 64 rALLy 64 Aurora kinase 64 Faslodex 64 paclitaxel poliglumex 64 riociguat 64 CA4P 64 Randomized Phase 64 fosbretabulin 64 RoACTEMRA 64 motesanib 64 mg/m2 dose 64 interferon beta 1a 64 Metastatic Breast Cancer 64 Newly Diagnosed Multiple Myeloma 64 EpCAM 64 non resectable 64 brain metastases 64 Doxil 64 Capesaris 64 Phase 1b clinical trials 64 Phase Ib 64 Phase Ib clinical 64 Adjuvant Treatment 64 AVOREN 64 CCX# 64 letrozole Femara 64 untreated metastatic pancreatic 64 FOLPI 64 bone metastases 64 etoposide 64 oncolytic vaccine 64 Virulizin ® 64 ASA# 64 FOLFIRI alone 64 Renal Cell Carcinoma RCC 64 renal cell carcinoma 64 Ibritumomab Tiuxetan 64 Marqibo 64 topotecan 64 CD# antibody [001] 64 SABCS 64 liver metastases 64 bladder carcinoma 64 temozolomide TMZ 64 Abiraterone acetate 64 rALLy clinical trial 64 ospemifene 64 relapsed myeloma 64 Vidaza ® 64 tyrosine kinase inhibitor 64 PNP inhibitor 64 Campath alemtuzumab 64 sapacitabine 64 dacetuzumab 64 stage IIIA 64 Erlotinib 64 dose cohorts 64 dose melphalan 64 metastatic malignant melanoma 64 evaluating Actimmune 64 Femara letrozole 64 tiuxetan 64 multi kinase inhibitor 64 MEK inhibitor 64 Metastatic Prostate Cancer 64 infliximab monotherapy 64 dose escalation Phase 64 R#/MEM # 64 Allovectin 7 64 Kit CD# positive 64 cytokine refractory 64 HER2 overexpression 64 MDS AML 64 Vidofludimus 64 cisplatin 64 relapsed Acute Myeloid 64 cabazitaxel 64 Fulvestrant 64 including eniluracil ADH 64 rNAPc2 64 ELOXATIN 64 HER2 positive cancers 64 elagolix 64 mitogen activated ERK kinase 64 ON #.Na 64 Golimumab 64 vismodegib 64 antiretroviral naïve 64 Telcyta 64 paclitaxel Taxol 64 prostate cancer mCRPC 64 orally bioavailable 64 viral kinetics 64 GAMMAGARD 64 MORAb 64 Tesetaxel 64 Naive Patients 64 HCV RESPOND 2 64 Sapacitabine 64 EGFR tyrosine kinase inhibitor 64 BCR ABL inhibitor 64 locoregional recurrence 64 myelodysplastic syndrome MDS 64 mertansine 64 severe hypercholesterolemia 64 figitumumab 64 cisplatin vinorelbine 64 R sorafenib tablets 64 cyclophosphamide methotrexate 64 hematological malignancies 64 IMiDs 64 TELCYTA 64 Platinol ® 64 Phase #b/#a clinical 64 myelodysplastic syndromes MDS 64 histological subtypes 64 evaluating satraplatin 64 Metastatic Melanoma 64 ENMD # 64 RG# [001] 64 APOPTONE 63 Randomized Phase II 63 phase IIb trial 63 Phase 2a trial 63 evaluating Nexavar 63 metastatic carcinoma 63 Targretin capsules 63 Tamibarotene 63 Myocet 63 Pegylated Interferon 63 proteasome inhibitor 63 IAP inhibitors 63 rituximab 63 Onrigin 63 Mitoxantrone 63 CLARITY study 63 Lenalidomide 63 Afatinib 63 Zorbtive TM 63 Jevtana 63 XmAb# 63 nilotinib Tasigna 63 anthracycline containing 63 vinca alkaloids 63 androgen independent 63 Neuradiab 63 essential thrombocythemia ET 63 advanced HER2 positive 63 Intravenous CP 63 Anti Tumor Activity 63 Panitumumab 63 zalutumumab 63 vemurafenib 63 chemotherapeutic agents 63 mTOR mammalian target 63 R# #mg BID 63 tamibarotene 63 IMC #B 63 evaluating mipomersen 63 MKC# MT 63 PEGINTRON TM 63 alemtuzumab Campath 63 vascular disrupting agent 63 RhuDex R 63 fallopian tube cancers 63 EndoTAG TM -1 63 ularitide 63 APTIVUS ritonavir 63 myeloproliferative diseases 63 CALGB 63 Soft Tissue Sarcoma 63 receiving highly emetogenic 63 diagnosed GBM 63 Eribulin 63 telaprevir dosed 63 celgosivir 63 trans retinoic acid 63 GSK# [001] 63 evaluating REVLIMID 63 iniparib BSI 63 Daclizumab 63 antibody MT# 63 castrate resistant 63 PDE4 inhibitor 63 metastatic melanoma 63 TRAIL R1 63 treatment naïve genotype 63 evaluating Prochymal 63 Phase 2b Clinical Trial 63 MCSP respectively 63 pralatrexate 63 randomized controlled Phase 63 multicenter Phase 63 R lenalidomide 63 Rigel R# 63 PROVENGE sipuleucel T 63 epithelial ovarian 63 Azacitidine 63 nucleoside analog 63 selective modulator 63 Camptosar ® irinotecan 63 AAG geldanamycin analog 63 Genasense oblimersen sodium Injection 63 Follicular Lymphoma 63 HDAC Inhibitor 63 GVAX Pancreas Vaccine 63 angiogenesis inhibitor 63 NEUVENGE 63 paclitaxel chemotherapy 63 FOLOTYN 63 Relapsed Refractory Multiple Myeloma 63 refractory acute myeloid 63 Sanofi Aventis Taxotere 63 Pivotal Phase III 63 ribavirin RBV 63 eosinophilic asthma 63 PegIFN RBV 63 OXi# 63 Paraplatin ® 63 anti angiogenic therapy 63 epirubicin 63 recurrent ovarian 63 palifosfamide 63 chronic eosinophilic leukemia 63 EGFR tyrosine kinase inhibitors 63 randomized Phase III 63 FLT3 63 pharmacodynamic PD 63 myeloproliferative disorders 63 TNF Tumor Necrosis Factor 63 tumor subtypes 63 mitomycin 63 PSN# [002] 63 BARACLUDE ® 63 tyrosine kinase inhibitors TKIs 63 relapsed AML 63 DAVANAT 63 poly ADP ribose polymerase 63 sargramostim 63 locoregional 63 REVLIMID ® 63 mutated KRAS gene 63 chemotherapeutic agent 63 multitargeted 63 advanced medullary thyroid 63 obatoclax 63 COU AA 63 Tarceva erlotinib 63 Platinol 63 COPEGUS ribavirin 63 BRAF V#E mutation 63 R Saizen R 63 lorvotuzumab mertansine 63 refractory gout 63 mcg albinterferon alfa 2b 63 hematologic cancers 63 CBLC# 63 carboplatin chemotherapy 63 Atiprimod 63 taxane resistant 63 Meets Primary Endpoint 63 PEG Interferon lambda 63 humanised monoclonal antibody 63 biochemical relapse 63 operable breast cancer 63 diagnosed glioblastoma multiforme 63 CLL8 63 commercialize deforolimus 63 cytotoxic therapy 63 Symadex 63 recurrent glioma 63 Flu Cy 63 sarcoma melanoma 63 tesmilifene 63 CD# CEA 63 resectable 63 5-FU/LV 63 metastatic breast 63 Phase 2b clinical 63 protease inhibitor PI 63 AEGR 63 histone deacetylase inhibitor 63 Vectibix monotherapy 63 posaconazole 63 Zybrestat 63 Alemtuzumab 63 flutamide 63 Solid Tumors 63 Canvaxin TM 63 Pralatrexate 63 erlotinib Tarceva 63 relapsed acute myelogenous 63 protein kinase inhibitor